Italy's Angelini names new chief executive

Italy's Angelini names new chief executive
Pierluigi Antonelli has worked for Bristol-Myers Squibb, US-based Merck & Co and Novartis

13 March 2019 - Deborah Wilkes

Italy's Angelini Pharma has appointed former Novartis executive Pierluigi Antonelli as chief executive officer. He takes over from Gianluigi Frozzi.

The privately-held company pointed out Antonelli had more than 20 years of experience in the pharmaceutical industry.

Antonelli spent three years at Novartis where his positions included head of Europe at Novartis Oncology and head of Western Europe at Sandoz. He has also worked for Bristol-Myers Squibb and US-based Merck & Co.

Commenting on his appointment, Antonelli said that with the support of the Angelini family he was committed to developing Angelini Pharma into a leading European player. He promised to expand both Angelini's geographic footprint and its prescription and OTC portfolio.

Angelini Pharma recorded sales of EUR881 million (USD997 million) in 2018, of which half was generated outside its home market of Italy. It has a direct presence in 18 countries and its products are marketed in more than 50 countries.

The company's consumer healthcare portfolio includes Amuchina disinfectants, Moment pain relievers, and Tantum Verde oral care and sore throat products. The products are available in Italy and a number of other countries including Portugal and Spain. 

Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions

Click tags below for more information on topics:


Back to Industry News

Share this page: